Suppr超能文献

人参(Panax)对人类糖尿病前期和 2 型糖尿病的疗效:系统评价和荟萃分析。

The Efficacy of Ginseng (Panax) on Human Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

机构信息

Research Center for Plants and Human Health, Institute of Urban Agriculture, Chengdu National Agricultural Science & Technology Center, Chinese Academy of Agricultural Sciences, Chengdu 610213, China.

Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, VIC 3168, Australia.

出版信息

Nutrients. 2022 Jun 9;14(12):2401. doi: 10.3390/nu14122401.

Abstract

Results from different clinical trials on the effects of ginseng on prediabetes and type 2 diabetes (T2DM) are still inconsistent. To fill this knowledge gap, we investigated the overall effects of ginseng supplementation on improving cardiometabolic biomarkers among these patients. A systematic literature search was conducted on PubMed/MEDLINE, Scopus, Web of Science, and Cochrane library. A random-effect model was applied to estimate the weighted mean difference and 95% CI for each outcome. Overall, 20 eligible RCTs were included. Meta-analyses revealed that ginseng supplementation significantly reduced serum concentration of FPG, TC, IL-6, and HOMA-IR values. It also increased HR and TNF-α levels. Ginseng supplementation changed HOMA-IR and HDL-C significantly based on dose and changed HOMA-IR and LDL-C significantly based on study duration in a non-linear fashion. Furthermore, meta-regression analyses indicated a linear relationship between ginseng dose and absolute changes in HDL-C. Moreover, subgroup analyses showed that ginseng supplementation changed TC and LDL-C when the supplementation dose was ≥2 g/day. Our findings suggest that ginseng supplementation may be an effective strategy for improving cardiometabolic profiles in individuals with prediabetes and T2DM.

摘要

结果来自人参对糖尿病前期和 2 型糖尿病(T2DM)影响的不同临床试验仍然不一致。为了填补这一知识空白,我们研究了人参补充剂对改善这些患者的心脏代谢生物标志物的总体影响。在 PubMed/MEDLINE、Scopus、Web of Science 和 Cochrane 图书馆上进行了系统的文献检索。应用随机效应模型估计了每个结果的加权均数差和 95%置信区间。总的来说,有 20 项符合条件的 RCT 被纳入。荟萃分析显示,人参补充剂可显著降低血清 FPG、TC、IL-6 和 HOMA-IR 值。它还增加了 HR 和 TNF-α 水平。根据剂量,人参补充剂可显著改变 HOMA-IR 和 HDL-C,根据研究持续时间,以非线性方式改变 HOMA-IR 和 LDL-C。此外,meta 回归分析表明,人参剂量与 HDL-C 的绝对变化之间存在线性关系。此外,亚组分析表明,当补充剂量≥2 g/天时,人参补充剂可改变 TC 和 LDL-C。我们的研究结果表明,人参补充剂可能是改善糖尿病前期和 T2DM 患者心脏代谢特征的有效策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dd0/9227417/9e4a5a4d3eb9/nutrients-14-02401-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验